Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director · President and CEO | September 08, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date September 08, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 522,968 |
Ending reported balance
After 2026-09-10 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-08 · Exercise / conversion · Acquired 54,174 · Balance 577,142 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Row 2 · 2026-09-08 · Sale · Disposed 54,174 · Balance 522,968 F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 3 · 2026-09-09 · Exercise / conversion · Acquired 63,548 · Balance 586,516 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Row 4 · 2026-09-09 · Sale · Disposed 63,548 · Balance 522,968 F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 5 · 2026-09-10 · Exercise / conversion · Acquired 7,278 · Balance 530,246 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Row 6 · 2026-09-10 · Sale · Disposed 7,278 · Balance 522,968 F4: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.58 · Expires 2026-10-11 | Direct | 70,826 |
Reported balance
After 2026-09-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-08 · Exercise / conversion · Disposed 54,174 · Balance 70,826 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.58 · Expires 2026-10-11 | Direct | 7,278 |
Reported balance
After 2026-09-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-09 · Exercise / conversion · Disposed 63,548 · Balance 7,278 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.58 · Expires 2026-10-11 | Direct | 0 |
Reported balance
After 2026-09-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-10 · Exercise / conversion · Disposed 7,278 · Balance 0 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 11, 2026 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 7,278 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-26-106831 · tm2625158-1_4seq1.xml · derivative · entry 9 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,278 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 7,278 | $144.10 | $1,048,759.80 |
DisclosureSEC source: 0001104659-26-106831 · tm2625158-1_4seq1.xml · nonDerivative · entry 6 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 522,968 F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 7,278 | $21.58 | $157,059.24 |
DisclosureSEC source: 0001104659-26-106831 · tm2625158-1_4seq1.xml · nonDerivative · entry 5 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 530,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 63,548 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-26-106831 · tm2625158-1_4seq1.xml · derivative · entry 8 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,278 Underlying: Common Stock · 63,548 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 63,548 | $146.18 | $9,289,446.64 |
DisclosureSEC source: 0001104659-26-106831 · tm2625158-1_4seq1.xml · nonDerivative · entry 4 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 522,968 F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 63,548 | $21.58 | $1,371,365.84 |
DisclosureSEC source: 0001104659-26-106831 · tm2625158-1_4seq1.xml · nonDerivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 586,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 54,174 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-26-106831 · tm2625158-1_4seq1.xml · derivative · entry 7 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,826 Underlying: Common Stock · 54,174 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 54,174 | $145.87 | $7,902,361.38 |
DisclosureSEC source: 0001104659-26-106831 · tm2625158-1_4seq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 522,968 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 54,174 | $21.58 | $1,169,074.92 |
DisclosureSEC source: 0001104659-26-106831 · tm2625158-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 577,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 21:14 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 510 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105955 · tm2624993-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,968 F1 · kind: This transaction involves a bona fide gift of securities from the Reporting Person to relatives. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 22:43 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 34,239 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-26-095111 · tm2622954-1_4seq1.xml · derivative · entry 6 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 34,239 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 22:43 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 34,239 | $148.52 | $5,085,176.28 |
DisclosureSEC source: 0001104659-26-095111 · tm2622954-1_4seq1.xml · nonDerivative · entry 4 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 523,478 F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.64 to $151.30. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 22:43 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 34,239 | $21.58 | $738,877.62 |
DisclosureSEC source: 0001104659-26-095111 · tm2622954-1_4seq1.xml · nonDerivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 557,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 22:43 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 65,761 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-26-095111 · tm2622954-1_4seq1.xml · derivative · entry 5 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,239 Underlying: Common Stock · 65,761 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 22:43 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 65,761 | $149.11 | $9,805,622.71 |
DisclosureSEC source: 0001104659-26-095111 · tm2622954-1_4seq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 523,478 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.41 to $151.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 22:43 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 65,761 | $21.58 | $1,419,122.38 |
DisclosureSEC source: 0001104659-26-095111 · tm2622954-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 589,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Read SEC document |
| May 12, 2026 Filed May 12, 2026 23:28 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-26-059591 · tm2614444-1_4seq1.xml · derivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 75,000 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options are fully vested and will expire on October 11, 2026. Read SEC document |
| May 12, 2026 Filed May 12, 2026 23:28 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 75,000 | $100.12 | $7,509,000.00 |
DisclosureSEC source: 0001104659-26-059591 · tm2614444-1_4seq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,478 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2026 Filed May 12, 2026 23:28 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 75,000 | $21.58 | $1,618,500.00 |
DisclosureSEC source: 0001104659-26-059591 · tm2614444-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 598,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2026 Filed May 15, 2026 00:06 UTC Amendment | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-26-061476 · tm2614674-1_4aseq1.xml · derivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 75,000 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested and will expire on October 11, 2026. Read SEC document |
| May 12, 2026 Filed May 15, 2026 00:06 UTC Amendment | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 75,000 | $100.12 | $7,509,000.00 |
DisclosureSEC source: 0001104659-26-061476 · tm2614674-1_4aseq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 523,478 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2026 Filed May 15, 2026 00:06 UTC Amendment | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 75,000 | $21.58 | $1,618,500.00 |
DisclosureSEC source: 0001104659-26-061476 · tm2614674-1_4aseq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 598,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This Form 4 Amendment is being filed to clarify that the transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026 and to check the appropriate box which appeared unchecked on the original Form 4 filing. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-048572 · tm2612651-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,478 F1 · kind: This transaction involves a bona fide gift of securities from the Reporting Person to family and friends. Read SEC document |
| March 25, 2026 Filed Mar 25, 2026 23:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 54,641 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001104659-26-034736 · tm269861-1_4seq1.xml · derivative · entry 7 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,641 shares Expires 2028-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| March 25, 2026 Filed Mar 25, 2026 23:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 54,641 | $101.00 | $5,518,741.00 |
DisclosureSEC source: 0001104659-26-034736 · tm269861-1_4seq1.xml · nonDerivative · entry 5 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,938 Read SEC document |
| March 25, 2026 Filed Mar 25, 2026 23:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 54,641 | $8.58 | $468,819.78 |
DisclosureSEC source: 0001104659-26-034736 · tm269861-1_4seq1.xml · nonDerivative · entry 4 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 579,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 23:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 59 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001104659-26-034736 · tm269861-1_4seq1.xml · derivative · entry 6 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,641 Underlying: Common Stock · 59 shares Expires 2028-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 23:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 59 | $101.00 | $5,959.00 |
DisclosureSEC source: 0001104659-26-034736 · tm269861-1_4seq1.xml · nonDerivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,938 Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 23:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 59 | $8.58 | $506.22 |
DisclosureSEC source: 0001104659-26-034736 · tm269861-1_4seq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 23:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-034736 · tm269861-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,938 F1 · kind: This transaction involves a bona fide gift of securities from the Reporting Person to relatives. F2 · balance_after: Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 4,068 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · derivative · entry 13 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 4,068 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: These stock options are fully vested and will expire on October 11, 2026. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 4,068 | $83.19 | $338,416.92 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · nonDerivative · entry 9 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,505 F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.06 to $83.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 4,068 | $21.58 | $87,787.44 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · nonDerivative · entry 8 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 14,205 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · derivative · entry 12 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,068 Underlying: Common Stock · 14,205 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: These stock options are fully vested and will expire on October 11, 2026. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 10,685 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · derivative · entry 11 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,685 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These stock options are fully vested and will expire on April 29, 2026. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 14,205 | $84.05 | $1,193,930.25 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · nonDerivative · entry 7 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,505 F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.075. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 14,205 | $21.58 | $306,543.90 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · nonDerivative · entry 6 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 10,685 | $84.00 | $897,540.00 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · nonDerivative · entry 5 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,505 F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.095. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 10,685 | $4.21 | $44,983.85 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · nonDerivative · entry 4 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 585,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 19,315 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · derivative · entry 10 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,685 Underlying: Common Stock · 19,315 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These stock options are fully vested and will expire on April 29, 2026. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 19,315 | $84.59 | $1,633,855.85 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · nonDerivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,505 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84.41 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 19,315 | $4.21 | $81,316.15 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 593,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-007129 · tm264253-3_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,505 F1 · kind: On January 23, 2026, the Reporting Person made a charitable donation of 6,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 22:16 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 34,438 | $82.48 | $2,840,446.24 |
DisclosureSEC source: 0001104659-26-005442 · tm263774-2_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,505 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:38 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 120,200 | $0.00 Strike: $87.18 | $0.00 |
DisclosureSEC source: 0001104659-26-001474 · tm262304-3_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,200 Underlying: Common Stock · 120,200 shares Expires 2036-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:38 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 95,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-001474 · tm262304-3_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 614,943 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 21:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 440 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-115399 · tm2532034-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,543 F1 · kind: This transaction involves a bona fide gift of securities from the Reporting Person to his grandchild. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 21:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 620 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-091352 · tm2526384-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,983 F1 · kind: This transaction involves a bona fide gift of securities from the Reporting Person to his son. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 22:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 10,415 | $54.78 | $570,533.70 |
DisclosureSEC source: 0001104659-25-071262 · tm2521838-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,603 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $54.75 to $54.82. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 23, 2025 Filed Jul 23, 2025 22:57 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 17,520 | $54.79 | $959,920.80 |
DisclosureSEC source: 0001104659-25-070104 · tm2521572-1_4seq1.xml · nonDerivative · entry 4 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,018 F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $54.75 to $55.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.